Entrada Therapeutics, Inc.

TRDA

$7.44

+$0.08 (1.14%)

Closed

Loading chart...

IndexN/A

Market Cap0.30B

Enterprise Value0.39B

Income$-0.02B

Sales$0.02B

EmployeesN/A

P/E-1.93

P/S16.73

P/B1.39

P/C-3.28

EV/EBITDA-2.71

EV/SalesN/A

EPS (ttm)-3.99

EarningsN/A

Gross Margin83.89%

Oper. Margin-613.66%

Profit Margin-565.48%

Volume0.36M

Shs Outstand0.04B

Change1.71%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Jun 811:08AMEntrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript(seekingalpha.com)

Jun 410:00AMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA(prnewswire.com)

Jun 205:04PMINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA(globenewswire.com)07:00AMIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study

Insider Trading

View All

Insider

Type

Price

Value

Date

Zeiher Bernhardt G

Award

19.0K

$5.97

$113K

Jun 10, 26

Thistle Mary

Award

19.0K

$5.97

$113K

Jun 10, 26

Radhakrishnan Maha

Award

19.0K

$5.97

$113K

Jun 10, 26

Chapman Gina

Award

19.0K

$5.97

$113K

Jun 10, 26

KIM PETER S

Award

19.0K

$5.97

$113K

Jun 10, 26

Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.

CEO: Dipal DoshiEmployees: 183www.entradatx.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$210.78M	$129.01M	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	$326.00K	$104.00K
Gross Profit	$210.78M	$129.01M	N/A	N/A	$-326.00K	$-104.00K
Gross Margin	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$163.77M	$132.18M	$97.25M	$51.13M	$26.34M	$11.72M
Operating Income	$47.01M	$-3.16M	$-97.25M	$-51.13M	$-26.67M	$-11.82M
Operating Margin	22.30%	-2.45%	0.00%	0.00%	0.00%	0.00%
Net Income	$65.63M	$-6.68M	$-94.62M	$-51.16M	$-26.52M	$-4.65M
Net Margin	31.13%	-5.18%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$1.76	$-0.20	$-2.79	$-1.60	$-0.84	$-4.44
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A

Entrada Therapeutics, Inc.

Insider Trading

Discover more